Add-On: Helicobacter pylori EIA

This is a single-marker test measuring Helicobacter pylori. It is available only as an add-on to the GI Effects® profile.

What is the Add-On: Helicobacter pylori By Genova Diagnostics?

The Helicobacter pylori EIA stool test is an enzyme immunoassay (EIA) used to detect the presence of Helicobacter pylori (H. pylori) antigens in stool samples. 

Helicobacter pylori (previously known as Campylobacter pylori) is a gram-negative, microaerophilic, spiral bacterium.  It’s estimated that up to 50% of the world’s population carries H. pylori.  [1.]  It is transmitted between humans in saliva, feces, or vaginal secretions.

This non-invasive test is employed for the diagnosis of H. pylori infection in the gastrointestinal tract. It works by detecting specific antigens produced by the bacterium in the stool specimen. 

Other tests for H. pylori are more invasive, requiring an endoscopy and biopsy for diagnosis.

The test is particularly useful in cases where other diagnostic methods, such as endoscopy with biopsy, are not feasible or desired. Additionally, the stool test is advantageous for monitoring the effectiveness of H. pylori eradication therapy and for confirming successful eradication post-treatment. 

It offers a convenient and reliable alternative to invasive procedures for detecting H. pylori infection, and a simple and easy addition to the GI Effects profile.

Why is the Add-On: Helicobacter pylori Clinically Relevant?

The clinical impact of Helicobacter pylori (H. pylori) infection encompasses various gastroduodenal diseases, including gastritis, peptic ulcer disease (PUD), dyspepsia, and gastric cancer. 

Furthermore, the presence of certain virulence factors within H. pylori strains, such as VacA and CagA, can influence the severity and progression of associated diseases, including gastric cancer. 

H. pylori causes hypochlorhydria, and may induce mucosal atrophy.  Symptoms associated with H. pylori include abdominal pain, chronic digestive issues, maldigestion, and dyspepsia.

Additionally, H. pylori infection may contribute to extra-gastroduodenal diseases including idiopathic thrombocytopenic purpura, iron deficiency anemia, insulin resistance, diabetes mellitus, non-alcoholic liver disease, metabolic syndrome, coronary artery disease, and neurodegenerative diseases, highlighting the importance of comprehensive management strategies.

Early detection and eradication of H. pylori are crucial for preventing the development of gastric malignancies and other gastroduodenal complications. [1.] 

Who Can Benefit From the Add-On: Helicobacter pylori by Genova Diagnostics?

Individuals experiencing symptoms of gastrointestinal distress such as chronic abdominal pain, bloating, nausea, vomiting, or unexplained weight loss.

Patients with suspected or diagnosed peptic ulcer disease (PUD), gastritis, or other gastroduodenal disorders.

Individuals with a history of H. pylori infection who require monitoring for recurrence or treatment effectiveness.

Those who are unable or unwilling to undergo invasive diagnostic procedures such as endoscopy with biopsy.

People with a family history of gastric cancer or other H. pylori-related complications.

Individuals with persistent dyspepsia or symptoms suggestive of functional dyspepsia.

Patients undergoing treatment for H. pylori infection to monitor response to therapy and ensure successful eradication.

Individuals with underlying conditions such as autoimmune diseases or chronic infections that may predispose them to H. pylori infection or complications.

Individuals at higher risk of H. pylori infection due to factors such as age, socioeconomic status, or geographical location.

Patients with recurrent or persistent gastrointestinal symptoms despite previous treatment, to assess for possible H. pylori involvement.

Collection and Shipping 

This test is an add-on, and it will be assessed in the sample provided by the patient for the full GI Effects profile.  Click here for Collection and Shipping Instructions.  

Additional Resources for Practitioners

Video: Interpreting the GI Effects Profile

Article: Using the GI Effects Test in Clinic

References

[1.] Mladenova I. Clinical Relevance of Helicobacter pylori Infection. J Clin Med. 2021 Aug 6;10(16):3473. doi: 10.3390/jcm10163473. PMID: 34441769; PMCID: PMC8396975.

[2.] Syam AF, Rani AA, Abdullah M, Manan C, Makmun D, Simadibrata M, Djojoningrat D, Sato T. Accuracy of Helicobacter pylori stool antigen for the detection of Helicobacter pylori infection in dyspeptic patients. World J Gastroenterol. 2005 Jan 21;11(3):386-8. doi: 10.3748/wjg.v11.i3.386. PMID: 15643676; PMCID: PMC4205343.